Macrogenics
Clinical trials sponsored by Macrogenics, explained in plain language.
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug combination (vobramitamab duocarmazine plus lorigerlimab) in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants received the drugs ev…
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 22, 2026 12:03 UTC
-
New drug combo shows promise in slowing Tough-to-Treat prostate cancer
Disease control CompletedThis study tested whether adding the experimental drug lorigerlimab to standard chemotherapy (docetaxel) can help men with a hard-to-treat type of prostate cancer live longer without their disease getting worse. About 150 men whose cancer had spread and stopped responding to horm…
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 18, 2026 11:47 UTC